Loading...
Publication
Papel da IL-17 na presença e progressão do cancro da cabeça e pescoço: revisão sistemática
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Projeto de pós-graduação_40483 | 1.18 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
O cancro da cabeça e pescoço (CCP) engloba um grupo diversificado de neoplasias, sendo os carcinomas de células escamosas da cavidade oral (COCE), orofaringe, nasofaringe e laringe os mais prevalentes. O CCP é o sétimo tipo de cancro mais comum na Europa e apresenta uma das piores taxas de sobrevivência, devido ao diagnóstico tardio em estádios avançados. Estudos sugerem que alterações genéticas e epigenéticas associadas a fatores de risco como o HPV podem estar envolvidas no desenvolvimento e progressão do CCP. A interleucina 17 (IL-17) e as células Th17 têm sido investigadas em diferentes tipos de cancro, incluindo o COCE, devido ao seu papel na resposta imunitária e na inflamação crónica. No entanto, a sua relação com o desenvolvimento tumoral permanece controversa. O objetivo desta revisão sistemática foi investigar o papel da IL-17 na presença e progressão do CCP. Seguindo as diretrizes Cochrane e PRISMA, foi realizada uma pesquisa bibliográfica nas bases de dados PubMed, Web of Science, B-On e Biblioteca Virtual em Saúde (BVS), com artigos publicados até dezembro de 2023. Foram identificados 315 artigos, dos quais 24 foram selecionados para análise metodológica qualitativa através do Joanna Briggs Institute Critical Appraisal Tools (JBI). Os 24 estudos incluíram um total de 1412 participantes e foram analisados de acordo com a localização anatómica do tumor. Os resultados demonstraram que, nas diferentes localizações anatómicas estudadas, a IL-17 esteve associada ao crescimento tumoral, apesar da escassez de dados sobre a sua relação com angiogénese e metastização. A plasticidade das células Th17 e a sua capacidade de alternar entre fenótipos Th17 e Treg destacam-se como mecanismos imunossupressores no microambiente tumoral. No caso do cancro da orofaringe, esta tendência pode ser influenciada pela presença do HPV, que promove a diferenciação Th1. A compreensão dessa dinâmica pode ser essencial para o desenvolvimento de estratégias terapêuticas personalizadas que utilizem a IL-17 como biomarcador no CCP.
Head and neck cancer (HNC) encompasses a diverse group of neoplasms, with squamous cell carcinomas of the oral cavity (OSCC), oropharynx, nasopharynx, and larynx being the most prevalent. HNC is the seventh most common cancer type in Europe and has one of the worst survival rates due to late-stage diagnoses. Studies suggest that genetic and epigenetic alterations associated with risk factors such as HPV may be involved in the initiation and progression of HNC. Interleukin 17 (IL-17) and Th17 cells have been investigated in various cancers, including OSCC, due to their role in immune response and chronic inflammation. However, their relationship with tumor development remains controversial. The objective of this systematic review was to investigate the role of IL-17 in the presence and progression of HNC. Following Cochrane and PRISMA guidelines, a literature search was conducted in the PubMed, Web of Science, B-On, and Virtual Health Library (VHL) databases, with articles available until December 2023. A total of 315 articles were identified, and 24 were selected for qualitative methodological analysis using the Joanna Briggs Institute Critical Appraisal Tools (JBI). The 24 studies included a total of 1412 participants and were analyzed based on tumor anatomical location. The results showed that, in the various anatomical locations studied, IL-17 was associated with tumor growth, despite limited data on its relationship with angiogenesis and metastasis. The plasticity of Th17 cells and their ability to switch between Th17 and Treg phenotypes stand out as immunosuppressive mechanisms in the tumor microenvironment. In oropharyngeal cancer, this trend may be influenced by the presence of HPV, which promotes Th1 differentiation. Understanding this dynamic could be crucial for developing personalized therapeutic strategies that use IL-17 as a biomarker in HNC.
Head and neck cancer (HNC) encompasses a diverse group of neoplasms, with squamous cell carcinomas of the oral cavity (OSCC), oropharynx, nasopharynx, and larynx being the most prevalent. HNC is the seventh most common cancer type in Europe and has one of the worst survival rates due to late-stage diagnoses. Studies suggest that genetic and epigenetic alterations associated with risk factors such as HPV may be involved in the initiation and progression of HNC. Interleukin 17 (IL-17) and Th17 cells have been investigated in various cancers, including OSCC, due to their role in immune response and chronic inflammation. However, their relationship with tumor development remains controversial. The objective of this systematic review was to investigate the role of IL-17 in the presence and progression of HNC. Following Cochrane and PRISMA guidelines, a literature search was conducted in the PubMed, Web of Science, B-On, and Virtual Health Library (VHL) databases, with articles available until December 2023. A total of 315 articles were identified, and 24 were selected for qualitative methodological analysis using the Joanna Briggs Institute Critical Appraisal Tools (JBI). The 24 studies included a total of 1412 participants and were analyzed based on tumor anatomical location. The results showed that, in the various anatomical locations studied, IL-17 was associated with tumor growth, despite limited data on its relationship with angiogenesis and metastasis. The plasticity of Th17 cells and their ability to switch between Th17 and Treg phenotypes stand out as immunosuppressive mechanisms in the tumor microenvironment. In oropharyngeal cancer, this trend may be influenced by the presence of HPV, which promotes Th1 differentiation. Understanding this dynamic could be crucial for developing personalized therapeutic strategies that use IL-17 as a biomarker in HNC.
Description
Keywords
Interleucina 17 Cancro da cabeça e pescoço Células Th17 Interleukin 17 Head and neck cancer Th17 cells